Aphios Corporation - Product Pipeline Review - 2016

Published: Feb, 2016 | Pages: 53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Aphios Corporation - Product Pipeline Review - 2016

Summary


Global Markets Direct's, 'Aphios Corporation - Product Pipeline Review - 2016', provides an overview of the Aphios Corporation's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Aphios Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Aphios Corporation
- The report provides overview of Aphios Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Aphios Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Aphios Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy


- Evaluate Aphios Corporation's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Aphios Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Aphios Corporation's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Aphios Corporation Snapshot 7
Aphios Corporation Overview 7
Key Information 7
Key Facts 7
Aphios Corporation - Research and Development Overview 8
Key Therapeutic Areas 8
Aphios Corporation - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Aphios Corporation - Pipeline Products Glance 16
Aphios Corporation - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Aphios Corporation - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Aphios Corporation - Drug Profiles 20
APH-0812 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
APH-0703 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
AMPI-109 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
APH-0201 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
APH-0701 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
APH-0907 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
APH-0911 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
APH-0912 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
APH-1201 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
APH-1305 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
camptothecin 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
dronabinol 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
HIV vaccine 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Hypericin 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
paclitaxel 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
paclitaxel phospholipid 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Sperol 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
APH-0202 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
APH-0804 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
APH-1403 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
APP-0205 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
APP-069 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
APP-309 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
APP-401 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Marinus 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Aphios Corporation - Pipeline Analysis 45
Aphios Corporation - Pipeline Products by Target 45
Aphios Corporation - Pipeline Products by Route of Administration 46
Aphios Corporation - Pipeline Products by Molecule Type 47
Aphios Corporation - Pipeline Products by Mechanism of Action 48
Aphios Corporation - Recent Pipeline Updates 49
Aphios Corporation - Dormant Projects 50
Aphios Corporation - Locations And Subsidiaries 51
Head Office 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List of Tables

Aphios Corporation, Key Information 7
Aphios Corporation, Key Facts 7
Aphios Corporation - Pipeline by Indication, 2016 10
Aphios Corporation - Pipeline by Stage of Development, 2016 12
Aphios Corporation - Monotherapy Products in Pipeline, 2016 13
Aphios Corporation - Partnered Products in Pipeline, 2016 14
Aphios Corporation - Partnered Products/ Combination Treatment Modalities, 2016 15
Aphios Corporation - Phase II, 2016 16
Aphios Corporation - Phase I, 2016 17
Aphios Corporation - Preclinical, 2016 18
Aphios Corporation - Discovery, 2016 19
Aphios Corporation - Pipeline by Target, 2016 45
Aphios Corporation - Pipeline by Route of Administration, 2016 46
Aphios Corporation - Pipeline by Molecule Type, 2016 47
Aphios Corporation - Pipeline Products by Mechanism of Action, 2016 48
Aphios Corporation - Recent Pipeline Updates, 2016 49
Aphios Corporation - Dormant Developmental Projects,2016 50